IDH1 and central nervous system cancer: Based on these preclinical evidence, several clinical trials are currently ongoing on mutant IDH1/2 glioma, including GBM, to evaluate the safety and efficacy of mutant IDH1 inhibitors (Ivosidenib, BAY1436032 and IDH305), mutant IDH2 inhibitor (Enasidenib), and pan-inhibitors inhibiting both mutant isoforms (Vorasidenib) [75–78].